The result was announced during trading hours today, 9 August 2012.

Meanwhile, the BSE Sensex was down 39.69 points, or 0.23%, to 17,560.87.

On BSE, 3.47 lakh shares were traded in the counter as against an average daily volume of 1.20 lakh shares in the past one quarter.

The stock hit a high of Rs 523.50 and a low of Rs 496.70 so far during the day. The stock had hit a 52-week high of Rs 542.15 on 29 May 2012. The stock had hit a 52-week low of Rs 366.50 on 19 December 2011.

The stock had outperformed the market over the past one month until 8 August 2012, rising 2.04% compared with the Sensex's 0.45% rise. The scrip had, however, underperformed the market in past one quarter, gaining 4.39% as against 6.37% rise in the Sensex.

India's largest drug maker by sales has an equity capital of Rs 211.13 crore. Face value per share is Rs 5.

Ranbaxy Laboratories' net sales jumped 54.49% to Rs 3174.06 crore in Q2 June 2012 over Q2 June 2011.

The depreciation of the Indian rupee (INR) against the US dollar (US$), though favourable to Ranbaxy's export business had an adverse impact on the company mainly on account of application of the accounting standards to marking to market the entire derivatives and foreign currency denominated loans outstanding. There was a net charge of $160 million (Rs 875.90 crore) on the P&L on account of the forex items.

Operating earnings before interest, tax, depreciation & amortization (EBITDA), excluding exceptional forex impact, was 16% of sales at Rs 511.30 crore in Q2 June 2012, up 142.32% against Rs 211 crore in Q2 June 2011.

Ranbaxy said sales and profitability improved over the corresponding period. Sales grew in major markets including USA, India, East Europe & CIS, West Europe and Africa over Q2 June 2011, on constant forex rates. The company said that USA sales were robust, helped by strong base business and exclusivity sales.

Emerging markets contributed $231 million, accounting for 39% of total consolidated sales. Developed markets recorded $328 million of sales and contributed 56% to total sales for the company. Active pharmaceutical ingredient (API) and others accounted for the rest of the revenue for the quarter.

North America sales surged 140% to Rs 1471.10 crore in Q2 June 2012 over Q2 June 2011, aided by strong base business and FTF sales. USA sales were Rs 1377.10 crore in Q2 2012.

India and Sri Lanka sales for the quarter were Rs 554 crore, growth of 13%, on rupee basis over Q2 2011.

Europe & Commonwealth of Independent States (CIS) sales for the quarter were Rs 552.50 crore, a growth of 19%, on constant forex basis over Q2 2011. Romania sales were Rs 111.70 crore, affected by additional claw-back charge impact taken during the Quarter. CIS sales were Rs 135.40 crore, growth of 28% on constant forex basis over Q2 2011.

APAC, ME, Africa, LATAM and API sales for the quarter were Rs 604.80 crore. Emerging market sales were impacted adversely in US Dollar terms due to the strengthening of the $ against such currencies.

Ranbaxy said that exclusivity of Atorvastatin and Atorvastatin+Amlodipine ended during the quarter. Ranbaxy said it attained peak market share of over 50% on both products during the exclusivity period. The company has maintained strong market share and leadership, even after the entry of multiple generic players post exclusivity.

India sales growth was 13% in INR terms. Sales grew faster than the segment growth in which the company participates.

During the quarter, Ranbaxy launched the first new drug from India, Synriam for the treatment of Plasmodium falciparum malaria, in adults.

Expanding on the Hybrid business model with Daiichi Sankyo (DS), Ranbaxy said it would introduce Sevikar, a fixed dose combination of Olmesartan Medoxomil and Amlodipine Pesylate in Romania.

Commenting on the business results for the quarter, Arun Sawhney, CEO & Managing Director, Ranbaxy, said, Sales and profitability grew in the Quarter with overall improvement across major regions, aided further by exclusivity sales in some of the key markets. We capitalized on our product focus approach with the successful monetization of the Atorvastatin and Atorvastatin + Amlodipine opportunities. The launch Synriam™, the first new drug from India was one of the high points of the quarter. The strategy to build long term, differentiated value drivers was rewarded with two NDA approvals in the dermatological space in the USA.

Ranbaxy Laboratories is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy is a member of the Daiichi Sankyo Group. Through strategic in-licensing opportunities and its hybrid business model with Daiichi Sankyo, a leading global pharma innovator headquartered in Tokyo, Japan, Ranbaxy is introducing many innovator products in markets around the world, where it has a strong presence. This is in line with the company's commitment to increase penetration and improve access to medicines, across the globe.

Powered by Capital Market - Live News